Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437839 | 0.87 | FFAR1 (0.45) | LMNAFFAR1FFAR4HSD17B10MEN1 | |
| SCHEMBL6437838 | 0.87 | FFAR1 (0.45) | LMNAFFAR1FFAR4HSD17B10MEN1 | |
| SCHEMBL31106015 | 0.85 | LMNA (0.54) | LMNAHSD17B10MEN1KMT2AFAAH | |
| SCHEMBL31106133 | 0.85 | LMNA (0.54) | LMNAHSD17B10MEN1KMT2AFAAH | |
| SCHEMBL31106219 | 0.85 | LMNA (0.54) | LMNAHSD17B10MEN1KMT2AFAAH | |
| SCHEMBL31105944 | 0.85 | LMNA (0.54) | LMNAHSD17B10MEN1KMT2AFAAH | |
| SCHEMBL31106101 | 0.85 | LMNA (0.54) | LMNAHSD17B10MEN1KMT2AFAAH | |
| SCHEMBL28049424 | 0.81 | FFAR1 (0.49) | LMNAFFAR1FFAR4HSD17B10MEN1 | |
| SCHEMBL28049400 | 0.81 | FFAR1 (0.45) | LMNAFFAR1FFAR4HSD17B10KMT2A | |
| SCHEMBL28049354 | 0.81 | FFAR1 (0.49) | LMNAFFAR1FFAR4HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102770121-B | Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue | LEO PHARMA A/S (DK) | 2014-10-15 | — | — | CN | claimed |
| EP-2515866-B1 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA AS (DK) | 2014-02-19 | — | — | EP | claimed |
| US-20130023501-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA A/S (DK) | 2013-01-24 | — | — | US | claimed |
| CN-102770121-A | Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue | LEO PHARMA AS | 2012-11-07 | — | — | CN | claimed |
| EP-2515866-A2 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | Leo Pharma A/S (DK) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076209-A2 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA A/S (DK) | 2011-06-30 | — | — | WO | claimed |
| EP-2515866-B1 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA AS (DK) | 2014-02-19 | — | — | EP | disclosed |
| US-20130023501-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA A/S (DK) | 2013-01-24 | — | — | US | disclosed |
| EP-2515866-A2 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | Leo Pharma A/S (DK) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076209-A2 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | LEO PHARMA A/S (DK) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023501-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE | VDR, CYP24A1, CYP2R1 | LMNA 1732/4885FFAR1 250/4885FFAR4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.